P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages

January 25, 2021 Auto Bot Covid-19 testing, License Agreement, Market, Partners, regulatory, Signs 0

Shots:

  • Rhinostics plans to register the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing for detection of SARS-CoV-2 infection
  • Rhinostics Standard Nasal Swab is a polypropylene collection device developed in partnership with P&G for COVID-19 testing which provides sample concentration of up to 30-fold over other swabs in viral transport media
  • The swab increases COVID testing efficiencies being applicable to broader respiratory viral, bacterial, and genetic testing using the PCR and NGS

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Packaging Europe

The post P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages first appeared on PharmaShots.